Status:
COMPLETED
Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer
Lead Sponsor:
University Hospital, Antwerp
Collaborating Sponsors:
Universiteit Antwerpen
Sanofi
Conditions:
Non-small Cell Lung Cancer
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage IB-II Non-...
Eligibility Criteria
Inclusion
- completely resected pathological stage IB or II NSCLC
- adequate haematological, renal and liver function and condition
Exclusion
- previous chemo or radiotherapy for NSCLC
- bronchoalveolar cell subtype
- second active primary malignancy or serious concomitant medical disease
- difficulties with adequate follow-up
Key Trial Info
Start Date :
December 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 1 2010
Estimated Enrollment :
99 Patients enrolled
Trial Details
Trial ID
NCT00434668
Start Date
December 1 2005
End Date
November 1 2010
Last Update
November 30 2010
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
ZNA Middelheim
Antwerp, Antwerp, Belgium, 2020
2
University Hospital Antwerp
Edegem, Antwerp, Belgium, 2650
3
St Augustinus ziekenhuis
Wilrijk, Antwerp, Belgium, 2610